Reversible Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma / 대한내과학회지
Korean Journal of Medicine
;
: 459-463, 2015.
Artículo
en Coreano
| WPRIM
| ID: wpr-194217
ABSTRACT
Bortezomib (Velcade(R)) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition of intracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells. It has been hypothesized that the accumulation of damaged proteins in myocytes impairs cardiac function. Cardiotoxicity is a rare side effect of bortezomib treatment. We report a case of reversible systolic heart failure that probably occurred after bortezomib treatment in a patient with multiple myeloma. Patients being treated with bortezomib who have previously had cardiac comorbidities should undergo routine cardiac monitoring.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Comorbilidad
/
Apoptosis
/
Células Musculares
/
Insuficiencia Cardíaca Sistólica
/
Bortezomib
/
Insuficiencia Cardíaca
/
Mieloma Múltiple
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS